Dashboard
1
Poor Management Efficiency with a low ROCE of 6.87%
- The company has been able to generate a Return on Capital Employed (avg) of 6.87% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -2.49% and Operating profit at -177.04% over the last 5 years
3
Negative results in Mar 25
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 555 Million (Small Cap)
NA (Loss Making)
NA
0.38%
-0.12
-1.05%
0.45
Revenue and Profits:
Net Sales:
86 Million
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.63%
0%
-16.63%
6 Months
-19.4%
0%
-19.4%
1 Year
15.01%
0%
15.01%
2 Years
-13.6%
0%
-13.6%
3 Years
0.26%
0%
0.26%
4 Years
-23.29%
0%
-23.29%
5 Years
-47.8%
0%
-47.8%
Guangzhou LBP Medicine Science & Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.49%
EBIT Growth (5y)
-177.04%
EBIT to Interest (avg)
24.74
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
0.37
Tax Ratio
93.18%
Dividend Payout Ratio
43.94%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.87%
ROE (avg)
3.26%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.45
EV to EBIT
-13.15
EV to EBITDA
28.83
EV to Capital Employed
0.38
EV to Sales
1.02
PEG Ratio
NA
Dividend Yield
0.38%
ROCE (Latest)
-2.86%
ROE (Latest)
-1.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
85.70
71.80
19.36%
Operating Profit (PBDIT) excl Other Income
5.40
-7.20
175.00%
Interest
0.10
0.00
Exceptional Items
0.50
-0.40
225.00%
Consolidate Net Profit
-1.50
-12.20
87.70%
Operating Profit Margin (Excl OI)
-72.40%
-262.60%
19.02%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 19.36% vs -38.58% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 87.70% vs -46.99% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
466.30
492.70
-5.36%
Operating Profit (PBDIT) excl Other Income
39.10
51.70
-24.37%
Interest
0.90
1.00
-10.00%
Exceptional Items
-2.70
2.70
-200.00%
Consolidate Net Profit
14.90
21.00
-29.05%
Operating Profit Margin (Excl OI)
-15.80%
9.50%
-2.53%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -5.36% vs -2.11% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -29.05% vs -28.33% in Dec 2023
About Guangzhou LBP Medicine Science & Technology Co., Ltd. 
Guangzhou LBP Medicine Science & Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






